ZZ Biotech's Stroke Therapy Shuns the Herd Mentality
By Marie Powers
Wednesday, August 15, 2012
More than a decade after describing the anti-inflammatory, antithrombotic and neuroprotective effects of activated protein C (APC) in ischemic stroke and six years after forming a company to move that hypothesis toward treatment, ZZ Biotech LLC has advanced its initial compound, 3K3A-APC, into the clinic.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.